A股半年报预告收官：半数预喜，稀土黄金板块净利最高增超千倍

Core Viewpoint - The first half of 2025 A-share performance shows significant divergence among industries, with biopharmaceuticals, semiconductors, and gold sectors performing well, while traditional industries face considerable pressure [1] Company Performance - Zhongyan Chemical (600328.SH) reported a revenue of 5.998 billion yuan, a year-on-year decrease of 5.76%, and a net profit of 52.7155 million yuan, down 88.04% year-on-year, attributed to macroeconomic conditions and demand fluctuations [3] - The company plans to enhance profitability through cost reduction and market structure adjustments, and aims to expand its market share in the natural soda ash sector [3] - As of July 14, 1013 A-share companies disclosed their 2025 semi-annual performance forecasts, with 516 companies (50.94%) expecting positive results, including 322 companies forecasting profit increases and 145 companies turning losses into profits [3] Industry Performance - The gold and rare earth sectors showed remarkable performance, with Shandong Gold (600547.SH) expecting a net profit of 2.55 to 3.05 billion yuan, a year-on-year increase of 84.3% to 120.5%, driven by rising gold prices and improved operational efficiency [4] - China Rare Earth (000831.SZ) is expected to turn a profit with a net profit forecast of 136 to 176 million yuan, due to product price recovery and reversal of inventory impairment [4] - In the biopharmaceutical sector, companies like WuXi AppTec (603259.SH) and Brother Technology (002562.SZ) reported net profit increases exceeding 100%, attributed to growing demand for innovative drug development and effective cost control [4] - The semiconductor industry also performed strongly, with companies like Rockchip (603893.SH) and Chipone (688582.SH) experiencing doubled earnings, driven by the surge in AI computing demand [4] - The civil aviation sector saw significant recovery, with Huaxia Airlines (002928.SZ) forecasting a net profit of 220 to 290 million yuan, a year-on-year increase of 741.3% to 1009.0%, benefiting from improved travel demand and optimized route networks [4] Market Analysis - Analysts indicate that the current performance divergence highlights structural opportunities, with biopharmaceuticals, technology, and resource companies showing strong earnings resilience, while traditional chemical and manufacturing sectors face challenges due to delayed demand recovery [5] - With ongoing growth stabilization policies, high-growth sectors are expected to see further improvement in performance certainty in the second half of the year [5]